Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Hosted on MSN7h
Pharma Stock Roundup: NVS, ABBV M&A Deals, FDA Nod to RHHBY, PFE Drugs
Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...
Moderna Stock Falls on Earnings Report. The Results Reaffirm a Grim Picture for Vaccine Maker.
Vaccine maker Moderna had no Valentine’s Day chocolates for investors when its financial results came out Friday. The company ...
pharmaphorum21h
FDA starts review of Pfizer, Lilly’s non-opioid painkiller
After years in development, the FDA has started its review of Pfizer and Eli Lilly’s new painkiller tanezumab, one of two remaining drugs in the ill-fated nerve growth factor (NGF) inhibitor class.
Yahoo Finance21h
Modine Manufacturing Company (MOD)
Do the numbers hold clues to what lies ahead for the stock? On a per-share basis, the Racine, Wisconsin-based company said it had net income of 76 cents. Earnings, adjusted for non-recurring costs ...
Yahoo Finance22h
Exact Sciences Corporation (EXAS)
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
MarketWatch16h
Annaly Capital Management Inc.
AGNC Investment Corp. Dep. Pfd. (Rep. 6.875% Cum. Redeem. Pfd. Series D 0.20% AGNC Investment Corp. Dep. Pfd. (Rep. 1/1000th Pfd. Series C) 0.31% AGNC Investment Corp ...